|
|
|
|
|
|
Obecure has chosen to operate through an outsourcing model, which enables the Company's small management team to cost-effectively orchestrate its entire clinical and preclinical development progress. By using this model, the company avoids the fixed costs associated with infrastructural setup and taps into the expertise of each of its contractors in manufacturing, analysis, clinical development and regulatory know-how. This enables Obecure to concentrate its resources on value creation as opposed to overhead expenses and mitigates the risk of development. |
|
|
|
|
|
|
| |
Contract Research Organizations:
Obecure has retained leading contract research organizations (CROs) as service providers to conduct its development program, including: |
| |
Clinical Operations |
| · |
Medpace |
| · |
Syreon |
| |
Biovail |
| · |
Pierrel Research Romania
|
| |
|
| |
Analytical and Manufacturing
|
| · |
SGS Labs |
| · |
ACE Pharmaceuticals |
| |
|
| |
Academic Collaborations: |
| · |
The National Institutes of Health (NIH) has agreed to sponsor and conduct a clinical study to evaluate the effect of OBE101 on energy consumption and expenditure.
|
| |
|
| · |
|
Formulation and Supply:
|
Obecure has an agreement with Farmaceutici Farmaceutici-Formenti SPA, the Italian subsidiary of the Grunenthal Group, a manufacturer of Microser ® (Betahistine dihydrochloride, 8, 16 and 24 mg) for the supply of Microser ® -24 for its clinical studies. Recently, the agreement has been extended to include license and supply of Microser -32XR, a proprietary extended release formulation of betahistine developed by Farmaceutici-Formenti. |
|
| |
|
 |
|
|
|
|
|
|
|
